News
GILD
--
0.00%
--
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
 
Benzinga · 15h ago
The Zacks Analyst Blog Highlights JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical
JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical have been included in this Analyst Blog.
Zacks · 19h ago
SVB Securities Initiates Gilead Sciences at Market Perform With $68 Price Target
MT Newswires · 22h ago
Top Research Reports for JPMorgan, Gilead Sciences & CSX
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corporation (CSX).
Zacks · 3d ago
Gilead at Forefront of Herculean Effort to Combat COVID-19
In the winter 2019, Kavita Juneja found herself at the center of a maelstrom. A strange and deadly virus known as SARS-CoV-2 was hurtling across the globe.
News Direct · 3d ago
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
FOSTER CITY, Calif., May 19, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, fou...
Business Wire · 4d ago
Gilead Stock Earns Rating Upgrade After Quick Turnaround
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue?
Investor's Business Daily · 4d ago
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.
Zacks · 5d ago
Living with Metastatic Bladder Cancer: Joey's Journey
Joey sold his business and felt like he was living the American dream when his life was turned upside down in 2019. He was diagnosed with metastatic bladder cancer.
News Direct · 5d ago
Junshi, Biosciences, Vigonvita VV116 helps shed COVID virus faster when taken early - study
A study of Shanghai Junshi Biosciences' (OTCPK:SHJBF) and Vigonvita Life Sciences' VV116 showed that the oral drug helped shed virus faster in certain patients with COVID-19. VV116, a derivative of Gilead Sciences
Seekingalpha · 5d ago
China Junshi's potential COVID drug shows promise in small trial
reuters.com · 6d ago
BRIEF-Gilead And Kite Oncology To Highlight Advances Supporting New Innovations In Cancer Care At The Asco Annual Meeting
reuters.com · 6d ago
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be presented at the 2...
Business Wire · 6d ago
Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection
Benzinga · 6d ago
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
Zacks · 6d ago
Where Gilead Sciences Stands With Analysts
Over the past 3 months, 10 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade o...
Benzinga · 6d ago
Gilead granted FDA nod to resume HIV studies for injectable lenacapavir
Gilead Sciences (NASDAQ:GILD) announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold imposed on the company’s Investigational New Drug Application (IND) for injectable lenacapavir in HIV
Seekingalpha · 6d ago
Piper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral Rating
MT Newswires · 05/17 05:24
BRIEF-FDA Lifts Clinical Hold On Investigational Lenacapavir For Treatment And Prevention Of HIV
reuters.com · 05/16 20:13
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
FOSTER CITY, Calif., May 16, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenac...
Business Wire · 05/16 20:10
Webull provides a variety of real-time GILD stock news. You can receive the latest news about Gilead Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.